| Overview |
| bsm-70033M |
| CD71 Antibody |
| WB, IHC |
| Specific for endogenous levels of the ~98 kDa CD71 protein. |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Preparation of KG1 cells |
| Monoclonal |
| DF1513 |
| IgG1 |
| Lot Dependent |
| Purified by Protein G. |
| PBS |
| Recommended that the undiluted antibody be aliquoted into smaller working volumes (10-30 uL/vial depending on usage) upon arrival and stored long term at -20° C or -80° C, while keeping a working aliquot stored at 4° C for short term. Avoid freeze/thaw cycles. Stable for at least 1 year. |
| Target |
| 7037 |
| P02786 |
| CD 71 antibody, CD71 antibody, CD71 antigen antibody, IMD46 antibody, OTTHUMP00000208523 antibody, OTTHUMP00000208524 antibody, OTTHUMP00000208525 antibody, p90 antibody, sTfR antibody, T9 antibody, TFR 1 antibody, TfR antibody, TfR1 antibody, TFR1_HUMAN antibody, TFRC antibody, TR antibody, Transferrin receptor (p90 CD71) antibody, Transferrin receptor protein 1, whole antiserum form antibody, Trfr antibody
|
| CD71, also known as the transferrin receptor (TfR1), is a transmembrane glycoprotein whose primary function is to mediate cellular uptake of iron from a plasma glycoprotein, transferrin. CD71 is a widely used marker for cell activation or proliferation of lymphocytes as transferrin receptor expression is undetectable in resting T and B lymphocytes, but increases significantly upon lymphocyte antigen activation (Galbraith, R.M., et al 1981). Rapidly proliferating cells and energy-requiring cells, like cancer cells, osteoclasts (Roodman, G.D., 2009), and activated lymphocytes (Wieland, E., et al, 2016) express high levels of CD71 due to increased iron demand. TfR1 is seen as an efficient drug delivery system for cancer patients as it can mediate extracellular transferrin conjugated molecules for treatment (Luria-Perez, R., et al, 2016). |
| Application Dilution |
| WB |
1:300-5000 |
| IHC |
|
Powered by Bioz